CoChat
Sign Up
Cited by 136COVID-19 Clinical Research StudiesDiabetes Management and ResearchCOVID-19 and healthcare impacts

COVID-19 and Diabetes: A Collision and Collusion of Two Diseases

Open access
Feldman, Eva L., Savelieff, Masha G., Hayek, Salim S., Pennathur, Subramaniam, Kretzler, Matthias, Pop-Busui, Rodica·2020·Diabetes
DOI 10.2337/dbi20-0032PMC PMC7679769
Open this paper in CoChat — free accountOpen PDF

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has infected >22.7 million and led to the deaths of 795,000 people worldwide. Patients with diabetes are highly susceptible to COVID-19–induced adverse outcomes and complications. The COVID-19 pandemic is superimposing on the preexisting diabetes pandemic to create large and significantly vulnerable populations of patients with COVID-19 and diabetes. This article provides an overview of the clinical evidence on the poorer clinical outcomes of COVID-19 infection in patients with diabetes versus patients without diabetes, including in specific patient populations, such as children, pregnant women, and racial and ethnic minorities. It also draws parallels between COVID-19 and diabetes pathology and suggests that preexisting complications or pathologies in patients with diabetes might aggravate infection course. Finally, this article outlines the prospects for long-term sequelae after COVID-19 for vulnerable populations of patients with diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dbi20-0032

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Efforts that succeed in halting the rise in diabetes could mitigate or delay associated health complications if implemented early.

    “Furthermore, efforts that succeed in halting the rise in diabetes could mitigate or delay associated health complications if implemented early.76, 77, 78, 79, 80”

    From Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 (2023) · cites this paper as [77]

    The Glycemic Control section reports better COVID-19 outcomes among people with diabetes whose blood glucose was well controlled. The Conclusions discuss improving care, but neither section addresses whether early efforts to halt the rise in diabetes could mitigate or delay its associated health complications; searches for diabetes prevention and early intervention found no such passage. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 78

  1. [2]Jin Y, Yang H, Ji W, Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12: 372 PMC7232198 32230900
  2. [3]Zhu L, She ZG, Cheng X, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31: 1068– 1077.e3 32369736 PMC7252168
  3. [5]Cummings MJ, Baldwin MR, Abrams D, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763– 1770 32442528 PMC7237188
  4. [6]Henderson LA, Canna SW, Schulert GS, On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 2020; 72: 1059– 1063 32293098 PMC7262347
  5. [9]Gianchandani R, Esfandiari NH, Ang L, Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes 2020; 69: 2048– 2053 32778570
  6. [10]Hui DS, Wong KT, Antonio GE, Tong M, Chan DP, Sung JJ Long-term sequelae of SARS: physical, neuropsychiatric, and quality-of-life assessment. Hong Kong Med J 2009; 15(Suppl. 8): 21– 23 20393208
  7. [11]Bauchner H, Golub RM, Zylke J Editorial Concern–Possible Reporting of the Same Patients With COVID-19 in Different Reports. JAMA 2020; 323: 1256 32176775
  8. [12]Wang D, Hu B, Hu C, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061– 1069 32031570 PMC7042881
  9. [13]Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054– 1062 32171076 PMC7270627
  10. [14]Guan WJ, Ni ZY, Hu Y,.; China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708– 1720 32109013 PMC7092819
  11. [15]Wu Z, McGoogan JM Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239– 1242 32091533
  12. [16]CDC COVID-19 Response Team Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 382– 386 32240123 PMC7119513
  13. [19]Suleyman G, Fadel RA, Malette KM, Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open 2020; 3: e2012270 32543702 PMC7298606
  14. [20]Petrilli CM, Jones SA, Yang J, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966 32444366 PMC7243801
  15. [21]Dreher M, Kersten A, Bickenbach J, The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int 2020; 117: 271– 278 32519944 PMC7171478
  16. [22]Wu C, Chen X, Cai Y, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934– 943 32167524 PMC7070509
  17. [23]Galloway JB, Norton S, Barker RD, A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study. J Infect 2020; 81: 282– 288 32479771 PMC7258846
  18. [24]Liang W, Liang H, Ou L,.; China Medical Treatment Expert Group for COVID-19 Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020; 180: 1081– 1089 32396163 PMC7218676
  19. [25]Cariou B, Hadjadj S, Wargny M,.; CORONADO investigators Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020; 63: 1500– 1515 32472191 PMC7256180
  20. [26]Barron E, Bakhai C, Kar P, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 2020; 8: 813– 822 32798472 PMC7426088
  21. [27]Zhang Y, Cui Y, Shen M,.; medical team from Xiangya Hospital to support Hubei, China Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study. Diabetes Res Clin Pract 2020; 165: 108227 32446795 PMC7242190
  22. [28]Guo W, Li M, Dong Y, Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; 36: e3319 PMC7228407 32233013
  23. [29]Iacobellis G, Penaherrera CA, Bermudez LE, Bernal Mizrachi E Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res Clin Pract 2020; 164: 108185 32360710 PMC7251996
  24. [30]Li Y, Han X, Alwalid O, Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study. Diabetes Res Clin Pract 2020; 166: 108299 32623030 PMC7332424
  25. [31]Chao WC, Tseng CH, Wu CL, Shih SJ, Yi CY, Chan MC Higher glycemic variability within the first day of ICU admission is associated with increased 30-day mortality in ICU patients with sepsis. Ann Intensive Care 2020; 10: 17 32034567 PMC7007493
  26. [32]Bode B, Garrett V, Messler J, Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020; 14: 813– 821 32389027 PMC7673150
  27. [33]Holman N, Knighton P, Kar P, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020: 8: 823– 833 32798471 PMC7426091
  28. [34]Zhang Y, Li H, Zhang J, The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: a single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab 2020; 22: 1443– 1454 32406594 PMC7273002
  29. [35]Wang S, Ma P, Zhang S, Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020; 63: 2102– 2111 32647915 PMC7347402
  30. [36]Smith SM, Boppana A, Traupman JA, Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol, 26 June 2020. Available from 10.1002/jmv.26227 PMC7361926 32589756 · DOI
  31. [37]Wang X, Fang X, Cai Z, Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. Research (Wash D C) 2020; 2020: 2402961 32377638 PMC7187729
  32. [38]Scheen AJ, Marre M, Thivolet C Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and other recent reports. Diabetes Metab 2020; 46: 265– 271 32447101 PMC7241378
  33. [39]Simonnet A, Chetboun M, Poissy J,.; LICORN and the Lille COVID-19 and Obesity study group High prevalence of obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020; 28: 1195– 1199 32271993 PMC7262326
  34. [40]Lassale C, Gaye B, Hamer M, Gale CR, Batty GD Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun 2020; 88: 44– 49 32497776 PMC7263214
  35. [41]Gao F, Zheng KI, Wang XB, Obesity is a risk factor for greater COVID-19 severity. Diabetes Care 2020;43: e72– e74 32409499
  36. [42]Callaghan BC, Reynolds EL, Banerjee M, The prevalence and determinants of cognitive deficits and traditional diabetic complications in the severely obese. Diabetes Care 2020; 43: 683– 690 31932459 PMC7035591
  37. [43]Shi Q, Zhang X, Jiang F, Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care 2020; 43: 1382– 1391 32409504
  38. [44]Guan WJ, Liang WH, Zhao Y,.; China Medical Treatment Expert Group for COVID-19 Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55: 2000547 32217650 PMC7098485
  39. [46]Patel NA Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 2020; 41: 102573 32531620 PMC7833675
  40. [47]Shekerdemian LS, Mahmood NR, Wolfe KK,.; International COVID-19 PICU Collaborative Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020; 174: 1– 6 PMC7489842 32392288
  41. [48]Chao JY, Derespina KR, Herold BC, Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City. J Pediatr 2020; 223: 14– 19.e2 32407719 PMC7212947
  42. [49]Zachariah P, Johnson CL, Halabi KC,.; Columbia Pediatric COVID-19 Management Group Epidemiology, clinical features, and disease severity in patients with Coronavirus Disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr. 3 June 2020 [Epub ahead of print]. DOI: 10.1001/jamapediatrics.2020.2430 PMC7270880 32492092 · DOI
  43. [50]Otto WR, Geoghegan S, Posch LC, The epidemiology of SARS-CoV-2 in a pediatric healthcare network in the United States. J Pediatric Infect Dis Soc. 19 June 2020 [Epub ahead of print] DOI: 10.1093/jpids/piaa074 PMC7337783 32559282 · DOI
  44. [51]Ebekozien OA, Noor N, Gallagher MP, Alonso GT Type 1 diabetes and COVID-19: preliminary findings from a Multicenter Surveillance Study in the U.S. Diabetes Care 2020; 43: e83– e85 32503837 PMC7372041
  45. [52]Sentilhes L, De Marcillac F, Jouffrieau C, Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet Gynecol. 15 June 2020 [Epub ahead of print]. DOI: 10.1016/j.ajog.2020.06.022 PMC7294260 32553908 · DOI
  46. [53]Lokken EM, Walker CL, Delaney S, Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington state. Am J Obstet Gynecol. 19 May 2020 [Epub ahead of print]. DOI: 10.1016/j.ajog.2020.05.031 PMC7234933 32439389 · DOI
  47. [54]Knight M, Bunch K, Vousden N,.; UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 2020; 369: m2107 32513659 PMC7277610
  48. [55]Kayem G, Lecarpentier E, Deruelle P, A snapshot of the Covid-19 pandemic among pregnant women in France. J Gynecol Obstet Hum Reprod 2020; 49: 101826 32505805 PMC7270811
  49. [56]El Chaar M, King K, Galvez Lima A Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates? Surg Obes Relat Dis 2020; 16: 1096– 1099 32522406 PMC7211681
  50. [57]Azar KMJ, Shen Z, Romanelli RJ, Disparities in outcomes among COVID-19 patients in A Large Health Care System In California. Health Aff (Millwood) 2020; 39: 1253– 1262 32437224
  51. [59]Bhargava A, Fukushima EA, Levine M, Predictors for severe COVID-19 infection. Clin Infect Dis 2020; 71: 1962– 1968 32472676 PMC7314166
  52. [60]Gold JAW, Wong KK, Szablewski CM, Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 545– 550 32379729 PMC7737948
  53. [61]Raisi-Estabragh Z, McCracken C, Bethell MS, Greater risk of severe COVID-19 in Black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J Public Health (Oxf) 2020; 42: 451– 460 32556213 PMC7449237
  54. [62]Millett GA, Jones AT, Benkeser D, Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol 2020; 47: 37– 44 32419766 PMC7224670
  55. [63]Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444– 1448 32132184 PMC7164635
  56. [64]Hoffmann M, Kleine-Weber H, Schroeder S, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271– 280.e8 32142651 PMC7102627
  57. [65]Felsenstein S, Herbert JA, McNamara PS, Hedrich CM COVID-19: immunology and treatment options. Clin Immunol 2020; 215: 108448 32353634 PMC7185015
  58. [66]Drucker DJ Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev 2020; 41: bnaa011 32294179 PMC7184382
  59. [67]Li MY, Li L, Zhang Y, Wang XS Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020; 9: 45 32345362 PMC7186534
  60. [68]Varga Z, Flammer AJ, Steiger P, Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417– 1418 32325026 PMC7172722
  61. [69]Biessels GJ, Despa F Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 2018; 14: 591– 604 30022099 PMC6397437
  62. [71]Kunutsor SK, Laukkanen JA Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med 2020; 52: 345– 353 32643418 PMC7877945
  63. [72]Yang JK, Lin SS, Ji XJ, Guo LM Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010; 47: 193– 199 19333547 PMC7088164
  64. [73]Caruso P, Longo M, Esposito K, Maiorino MI Type 1 diabetes triggered by covid-19 pandemic: a potential outbreak? Diabetes Res Clin Pract 2020; 164: 108219 32442555 PMC7237369
  65. [74]Unsworth R, Wallace S, Oliver NS, New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care 2020; 43: e170– e171 32816997
  66. [75]Bansal R, Gubbi S, Muniyappa R Metabolic syndrome and COVID 19: endocrine-immune-vascular interactions shapes clinical course. Endocrinology 2020; 161: bqaa112 32603424 PMC7337756
  67. [76]Zheng Z, Peng F, Xu B, Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020; 81: e16– e25 PMC7177098 32335169
  68. [78]Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep 2016; 16: 29 26897744 PMC5127166
  69. [79]Abbasi A, Corpeleijn E, Postmus D, Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia 2011; 54: 2463– 2465 21674177
  70. [80]Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 2020; 24: 187 32354367 PMC7191969
  71. [81]Heraclides A, Jensen TM, Rasmussen SS, The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia 2013; 56: 1542– 1546 23613086
  72. [82]Hayek SS, Sever S, Ko YA, Soluble urokinase receptor and chronic kidney disease. N Engl J Med 2015; 373: 1916– 1925 26539835 PMC4701036
  73. [83]Hayek SS, Divers J, Raad M, Predicting mortality in African Americans with type 2 diabetes mellitus: soluble urokinase plasminogen activator receptor, coronary artery calcium, and high-sensitivity C-reactive protein. J Am Heart Assoc 2018; 7: e008194 29716888 PMC6015289
  74. [85]Batawi S, Tarazan N, Al-Raddadi R, Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes 2019; 17: 101 31186042 PMC6560892
  75. [86]Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020; 5: 831– 840 32219363
  76. [87]Ceriello A, Standl E, Catrinoiu D,.; Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care 2020; 43: 1427– 1432 32409501
  77. [88]Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 2020; 194: 105921 32422545 PMC7227498
  78. [90]Xiang YT, Yu X, Ungvari GS, Correll CU, Chiu HF Outcomes of SARS survivors in China: not only physical and psychiatric co-morbidities. East Asian Arch Psychiatry 2014; 24: 37– 38 24676486

Cited by

Sorted by citations

Authors
Feldman, E. L., Savelieff, M. G., Hayek, S. S., Pennathur, S., Kretzler, M., & Pop-Busui, R.
Affiliations
  • University of Michigan (US)
  • Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Corresponding author
Feldman, Eva L.
ORCID
Venue
Diabetes
Publisher
American Diabetes Association
Published
2020-09-16
Volume
69
Issue
12
Pages
2549-2565
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
DOI
10.2337/dbi20-0032
PMC
PMC7679769
OpenAlex
W3085941542
Cited by
136
References
11
Citations by year
2026: 5 · 2025: 13 · 2024: 10 · 2023: 36 · 2022: 41 · 2021: 29 · 2020: 2
FWCI
1.28
Type
journal article
Language
en
Open access
Licence
www.diabetesjournals.org/content/license (vor, 65 d)
Locations
  • Diabetes (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (R01 DK107956, R24 DK082841, P30 DK081943, U01 DK119083, R01 HL15338401)
  • JDRF (5-COE-2019-861-S-B)
  • Frankel Cardiovascular Center (U-M G024231)
  • Michigan Center for Contextual Factors in Alzheimer’s Disease (P30-AG059300)
  • Michigan Institute for Clinical & Health Research (UL1-TR002240)
  • Michigan Economic Development Corporation (CASE-244578)
  • NeuroNetwork for Emerging Therapies
  • A. Alfred Taubman Medical Research Institute
  • Robert and Katherine Jacobs Environmental Health Initiative
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
Keywords
COVID-19 pandemic, comorbidities, clinical outcomes, children, pregnant women, racial and ethnic minorities, long-term sequelae, vulnerable populations, disease pathology
MeSH terms
COVID-19, SARS-CoV-2, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Risk Factors, Comorbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review